Biognosys, a global company specialising in mass spectrometry-based proteomics, and Alamar Biosciences, a company powering precision proteomics to enable the earliest detection of disease, have announced a strategic partnership aimed at advancing scientific discovery in the field of biofluid proteomics biomarkers.
This collaboration brings together Biognosys’ expertise in unbiased discovery through data independent acquisition mass spectrometry (DIA-MS) and Alamar’s immunoassays.
This integrated approach enhances our understanding of biomarkers by combining deep unbiased DIA-MS discovery proteomics with highly specific and ultra-sensitive mid- and high-plex NULISA assays for low-abundance proteins such as cytokines, chemokines and important disease protein biomarkers from plasma.
In the Industry Spotlight Theatre session hosted by Alamar at the American Society for Cancer Research (AACR) 2024 Annual Meeting in San Diego on April 9 at 12:30 pm PT, the companies will jointly present data from a collaborative study focused on Non-Small Cell Lung Cancer (NSCLC).
In this study, plasma samples from a cohort of NSCLC patients were analysed using both the discovery platform by Biognosys and Alamar’s inflammation sequencing platform.
The findings demonstrate the feasibility of integrated analysis and highlight the complementary insights derived from mass spectrometry and affinity-based assays in plasma.
Building upon this successful proof-of-concept study, Biognosys and Alamar are planning to further collaborate both commercially and scientifically as part of their strategic partnership.
- NULISA Assay Services: Biognosys will offer NULISA assays from its facility in Switzerland for previously hard to measure cytokines, chemokines, as well as other important disease specific markers from plasma and biofluids. These ultra-high sensitivity assays enable precise quantification of low abundance proteins, providing researchers with valuable insights into complex biological processes. They complement unbiased DIA-MS analysis of thousands of plasma proteins to elucidate systemic host response, and other inflammation or disease-related protein-fold changes.
- Research Collaboration: Biognosys and Alamar will embark on a joint research initiative to explore plasma biology. By leveraging Biognosys’ unbiased discovery methods alongside Alamar’s ultra-high sensitivity assays, the teams seek to unravel biological disease mechanisms by providing a more complete picture of the plasma proteome, enabling for the first time the coverage of essentially the complete dynamic range of protein abundance in plasma.
Oliver Rinner, Ph.D., Founder and CEO of Biognosys, expressed enthusiasm about the collaboration: “Our combined efforts will pave the way for breakthroughs in allow the unbiased proteomics analysis, including high value, low abundance proteins, as well as characterised cytokines.”
